A number of therapeutics have been found to be ineffective in as many as 75% of patients – a significant driver in the ongoing development of precision medicine. The use of biomarkers in the drug development process is becoming increasingly popular, with success rates as much as tripling when biomarkers are employed.
In line with the increasing prevalence of personalized and precision medicine, Cerba Research has ensured optimal value by expanding and diversifying its portfolio beyond routine efficacy and safety parameters. The company is dedicated to offering a comprehensive repertoire of next-generation assays.
Cerba Research is able to deliver targeted approaches, broad immune profiling and multifactorial biomarker approaches able to identify either single or multiple biomarkers. These approaches can be customized and adapted based on clinical trial stage and biomarker purpose; for example:
- Selection of guide doses
- Characterization of modes of action
- Patient stratification
- Drug response predictions
- Supporting the prognosis of patients
- Disease monitoring
There is no ‘one size fits all’ approach to biomarker development, so Cerba Research is dedicated to working in partnership with its customers to develop the right solution to meet their needs. These solutions may include:
- Transferring in-house developed assays
- Assessing the feasibility of methods
- Developing and validating customized assays
- Detailed sample analysis
The company’s comprehensive range of available solutions includes:
- Specialist testing
- Extensive scientific expertise
- Tailored and customized assays
- Quality control
Circulating biomarkers
Human plasma
| . |
| 4β-Hydroxcholesterol |
Factor V Activity |
IL-10 |
| α-GST |
Factor VII Activity |
IL-12p70 |
| Aβ-40 |
Factor VIII Activity |
IL-12/23p40 |
| Active B-12 |
Factor IX Activity |
IL-13 |
| Anti-lia |
Factor Xa |
IL-15 |
| Anti-Xa |
Factor X Activity |
IL-16 |
| Adiponectin |
Factor XI Activity |
IL-17A |
| Aldosterone |
Factor XII Activity |
IP-10 |
| Auristatin F and Auristatin F HPA |
Factor XIII Activity |
Lepin |
| bFGF |
Factor VIIIc |
MCP-1 |
| Brain Derived Neurotropic Factor (Free) |
Factor IX inhibiting antibodies |
MCP-4 |
| C3a (Complement 3a) |
Factor VIII inhibiting antibodies |
MDC |
| C4 (Complement 4) |
FGF23 |
MIP-1β |
| C5a (Complement 5a) |
Fibrinogen antigen |
NGAL |
| Cholesterol |
FLT-1 |
PAI-1 Ag |
| Cholic Acid |
Fructosamine |
PIGF |
| Clozapine |
FSH (follicle stimulating hormone) |
Protein C Activity |
| Cortisol |
GM-CSF |
Protein C Antigen |
| CRP |
GLP-1 |
Protein S Antigen free |
| Cystatin C |
Glucagon |
Protein S Total and free |
| DPPIV |
ICAM-1 |
Protein S Activity |
| Eotaxin |
IFNγ |
Osteocalcin |
| Eotaxin-3 |
IGF-2 |
VWF |
| Ergosterol |
IL-1α |
TARC |
| E-selectin |
IL-1β |
Tie-2 |
| Estrone/Equiline |
IL-2 |
TNFα |
| Estrone sulfate/Equiline sulfate |
IL-4 |
TNFβ |
| Ethyl Estradiol/Norgestimate/17-Desacetyl Norgestmate |
IL-5 |
VCAM-1 |
| Exendin 9-39 |
IL-6 |
VEGF-A |
| Factor II Activity |
IL-8 |
VEGF-D |
Human urine
| . |
| N2- (1-Carboxyethyl)-2'Deoxy-Guanosine (CEDG) |
| Cortisol/6β-hydroxycortisol |
| Creatine |
| CTx-II |
| Glucose |
| IL-18 |
| KIM-1 |
| NGAL |
| NTx |
Human serum
| . |
| Active B-12 |
Human IgG2 |
Leptin |
| Adiponectin |
Human IgG3 |
MCP-1 |
| Amyloid A |
Human IgG4 |
MCP-4 |
| Apolipoprotein A2 |
Human 90K/MAC-2BP |
MDC |
| Apolipoprotein C3 |
HMGB-1 |
MIP-1α |
| Apolipoprotein E |
ICAM-1 |
MIP-1β |
| APRIL |
IFN-α |
MMP-1 |
| ATX |
IFN-γ |
MMP-2 |
| BCMA |
IGF-1 |
MMP-3 |
| CCL18 |
IFG-2 |
MMP-7 |
| Chitinase 3-like 1 |
IGFPB-3 |
MMP-9 |
| Chromogranin A |
IL-1β |
MMP-12 |
| CK18 M30 |
IL-1RA |
MPO |
| CK18 M65 |
IL-2 |
Osteocalcin |
| Cortisol |
IL-4 |
PARC |
| C-peptide |
IL-5 |
S100A12 |
| CRP |
IL-6 |
SP-A |
| CXCL13 |
IL-6 sR |
SP-B |
| E-selectin |
IL-7 |
SP-C |
| Estradiol (E2) |
IL-8 |
SP-D |
| Ethisterone |
IL-10 |
sRF |
| Eotaxin |
IL-12 |
TARC |
| Eotaxin-3 |
IL-12p70 |
Tie-2 |
| FGF-19 |
IL-12/23p40 |
TiMP-2 |
| FGF-21 |
IL-13 |
TK-1 |
| Free fatty acids |
IL-15 |
TNFα |
| G-CSF |
IL-16 |
TNFβ |
| GDF-15 |
IL-17A |
VCAM-1 |
| GM-CSF |
IL-27 |
VEGF-A |
| Human IgG Total |
Inhibin-B |
VEGF-C |
| Human β-Defensin 2 (HBD2) |
IP-10 |
VEGF-D |
| Human IgG1 |
KL-6 |
|
Human cell/tissue
Whole blood
| . |
| Factor II G20210A |
| Factor V Leiden |
| HLA genotyping |
Human CSF
| . |
| Aβ-40 |
| Aβ42 |
| hTau Ag |
| Phospho-tau |
BAL fluid
Flow cytometry
Biomarkers
| . |
|
|
| ‘X’CAR-T |
Any CAR-T target 'X' |
Drug target |
| Bcl2 |
Apoptosis regulator |
Apoptosis regulator |
| BCMA |
B cells, plasma cells |
Checkpoint, immune cell regulation |
| CCR7 |
Memory and naive T cells |
Immunophenotyping: T cell activation |
| CD4 |
T helper, expressed by monocytes and macrophages |
Immunophenotyping: T cell activation |
| CD5 |
T cells, B cells |
Immunophenotyping: T cell suppression |
| CD8 |
T cells, NK cells |
Immunophenotyping: cytotoxic T cell = activated T cell |
| CD11b |
Monocytes, MDSCs, neutrophils and macrophages,
T cells, B cells, dendritic cells |
Immunophenotyping: T cell activation |
| CD14 |
Monocytes, macrophages, monocytic MDSCs, granulocytes |
Immune cell activation |
| CD15 |
Granulocytes, macrophages and monocytes |
Immune cell activation |
| CD16 |
T cells, dendritic cells, NK cells, macrophages
and monocytes, granulocytes |
Immune cell activation |
| CD19 |
B cells, dendritic cells, stem cells |
Immune cell regulation |
| CD25 |
T cells, B cells, NK cells, macrophages and monocytes |
Immune cell activation |
| CD27 |
T cells, B cells, NK cells |
Immune cell activation |
| CD28 |
T cells |
T cell proliferation |
| CD31 |
T cells, B cells, NK cells, macrophages and
monocytes, granulocytes, platelets |
Immune cell activation |
| CD33 |
Monocytes, MDSCs, neutrophils, macrophages |
Cell adhesion and signal transduction |
| CD38 |
T cells, B cells, dendritic cells, NK cells,
stem cells, macrophages and monocytes |
Cell adhesion and signal transduction |
| CD39 |
T cells, B cells, NK cells, macrophages and monocytes |
Immune cell regulation |
| CD45 |
Activated and memory T cells, some B cells subsets,
activated monocytes and macrophages, granulocytes,
NK cells, dendritic cells |
Immune cell regulation |
| CD47 |
T cells, B cells, NK cells, macrophages and
monocytes, granulocytes, platelets |
Cell adhesion and signal transduction |
| CD52 |
T cells, B cells, NK cells, macrophages and monocytes |
Immunophenotyping: cytotoxicity |
| CD56 |
T cells, NK cells |
Cell adhesion |
| CD69 |
T cells, B cells, NK cells, macrophages and
monocytes, granulocytes, platelets |
Immune cell proliferation and signal transduction |
| CD86 |
T cells, B cells, dendritic cells,
macrophages and monocytes |
T cell activation |
| CD117 |
Stem cells/precursor |
Immunophenotyping: cell adhesion immune cells |
| CD123 |
Dendritic cells, stem cells, granulocytes |
Immune cell differentiation |
| CD127 |
T cells, stem cells, macrophages and monocytes |
Immune cell activation |
| CD137 |
Activated T cells, NK cells |
Checkpoint: immune cell regulation |
| CD138 |
B cells, stem cells |
Immune cell activation, cell proliferation |
| CD314 |
T cells, B cells, NK cells, macrophages
and monocytes, granulocytes |
Immune cell regulation |
| CLL1 |
Car-T target |
Drug target |
| CXCR3 |
T cells |
T cell activation |
| CXCR4 |
Leukocytes, tumor cells |
Cell migration |
| HLA |
Antigen presenting cells |
Immune cell activation |
| Kappa |
Surface marker |
Diagnosis and identification of hematopoietic malignancies |
| Ki67 |
Tumor cells |
Tumor cell proliferation and growth |
| LAG3 |
Activated T cells |
Checkpoint, immune cell regulation |
| Lambda |
Surface marker |
Diagnosis and identification of hematopoietic malignancies |
| OX40 |
Activated T cells, NK cells, neutrophils |
Immune cell activation and differentiation |
| PD-1 |
Activated T cells, B cells |
Checkpoint: immune cell regulation |
| PD-L1 |
Tumor cells and immune cells including T cells,
B cells and antigen presenting cells |
Checkpoint: immune cell regulation |
| RQR8 |
B cells |
Safety switch |
| TIM3 |
T cells |
Checkpoint: immune cell regulation |
Flow cytometry panels and research
Available flow cytometry panels include:
Basic immune phenotyping panels
- TBNK (CD4/CD8 T cells, B cells, NK cells)
- T cell subsets (CD4/CD8 T cells)
T cell phenotyping panels
- T cell backbone (CD45/CD3/CD4/CD8)
- T cell activation (CD25/CD69/CD38)
- Regulatory T cells (CD25/CD127)
- T cell exhaustion(PD1/TIM3/LAG3)
- T cell proliferation and survival (Ki-67/Bcl-2)
- Naive and memory T cells (CD45RO/CD45RA/CD62L/CCR7/CD95)
B and NK cell panels
- B cell activation (CD45/viability/CD19/CD20/CD59/CD10/CD5)
- NK cell subsets (CD45/viability/CD3/CD16/CD56)
- NK cell activation (CD45/viability/CD3/CD16/CD56/CD158a;b/CD314/CD335)
Other immune cell panels
- Monocyte and neutrophil (CD45, CD14/CD15/CD11b)
- Extensive panel (CD16/CD64/CD300e)
- Monocytic MDSC (CD45/lineage/HLA-DR/CD11b/CD33/CD14/CD15)
- pDC and basophil (CD45/HLA-DR/CD123/BDCA2)
Multiple Myeloma panels are also available.
Histopathology
Special stains
| . |
| Alcian Blue |
| Alcian Blue/Periodic Acid-Schiff (PAS) |
| Alizarin Red |
| Azan Mallory |
| Bodian |
| Calleja |
| Giemsa |
| Gomori’s Elastin Trichrome |
| Gram |
| Hematoxylin Eosin (HE) |
| HE/Alcian Blue |
| Hematoxylin Eosin Saffron (HES) |
| Kluver-Barrera (Luxol Fast Blue) |
| Masson’s Trichrome |
| Methylen Blue |
| Movat Pentachrome |
| Oil Red O/Hematoxylin |
| Orcein |
| PAS |
| Sirius Red |
| Von Kossa |
Cerba Research offers an array of cutting-edge expertise, with central review, analysis and reporting services routinely delivered by Ph.D. scientists. Thanks to its international approach and global footprint, the company can also accommodate whole blood and bone marrow aspirates.
Harmonized flow cytometry services are available in Europe, Australia, the USA and Asia (including China). Tailored solutions are available throughout these territories, including customized, fit-for-purpose flow cytometry assays.
Customized validation and analysis services
Validated panels are available to accommodate a multitude of diseases, and Cerba Research has proven excellence in enhancing assay quality of assays.
Assay results can be provided in terms of relative %, absolute cell count, as well as fluorescence quantification.
Immuno-oncology and immuno-phenotyping tools are available to analyze:
- Regulatory T-cells (activation, proliferation, memory)
- B cell panel
- TBNK
- NK cell panel
Other available tools for biomarker development include:
- Pharmacodynamics (PD) analysis
- Receptor occupancy (RO) and pharmacodynamics (PD)
- Pharmacokinetic (PK) analysis
- Expression of therapy, activation, and expansion (CAR-T, CAR-NK)
Diagnosis and Prognosis are well served by Cerba Research’s receptor occupancy (RO) and pharmacodynamics (PD) tools, while follow-up on the evolution of therapy, expression of therapy, activation and expansion can benefit from the use of CAR-T and CAR-NK analysis.
Immunohistochemistry antibodies
| . |
|
|
| 4-1BB |
DDR1 |
MCL1 |
| 4HNE |
Dystrophine |
MelanA |
| 5T4 |
E-Cadherin |
Muc5AC |
| α-SMA |
Elastin |
Na/K ATPase |
| β-amyloid |
Elastin/Vimentin |
Nectin-1 |
| β-galactosidase |
Endocan |
OX-40 |
| ARGINASE 1 |
ER (Estrogen Receptor) |
p16 |
| BCL2 |
Erb BD |
p21 |
| BCLXL |
F4/80 |
p40 |
| BCM |
Fibrinogen |
p53 |
| CA 19-9 |
Fibroblast |
p63 |
| Caspase 3 |
Fibronectin |
PanKeratin |
| CC-10 |
Filaggrin |
PCNA |
| CD3 |
Fox J1 |
PD-1 |
| CD4 |
Foxp3 |
PD-L1 |
| CD8 |
GATA-3 |
pEGFR |
| CD11b |
GFAP |
pH2AX |
| CD14 |
GFP |
Plakoglobin |
| CD15 |
Glucagon |
p-Met |
| CD16 |
Glucagon/Insuline |
pS404 |
| CD20 |
H.Pylori |
PSMA |
| CD30 |
H2A1 |
pStat1 |
| CD31 |
HER2 |
pStat5 |
| CD39 |
HLA |
pTau |
| CD45 |
HLA-DR |
RIPK3 |
| CD47 |
HLA-E |
SCN5A |
| CD56 |
HLA-G |
SIRPa |
| CD68 |
hTERT |
SLC1A5 |
| CD73 |
HTRA2 |
Spectrin |
| CD94 |
IBA1/Map2 |
Synaptophysin |
| CD138 |
IDO |
TAU |
| CD144-VE Cadherin |
IFN gamma |
T-Bet |
| CD155 |
IL-1α |
TEAD1 |
| CD163 |
IL-1β |
TIGIT |
| CD226 |
IL-22 |
TIM-3 |
| CEA |
iNOS |
TNF-α |
| CK5/CK6 |
Insulin |
TNFRSF14/HVEM |
| C-Maf |
Integrin 1 |
Tryptase |
| C-Met |
Kappa |
TTF-1 |
| Collagen I |
Ki67 |
Tyrosine hydroxylase |
| Collagen I/Collagen III |
LAG-3 |
Vaccinia virus |
| Collagen III |
Lambda |
VCAM1 |
| Collagen IV |
Laminin |
VEGRF2 |
| Connexin 43 |
LC3B |
Vimentin |
| CTGF |
LDH |
VSIG4 |
| CTLA4 |
Lox-1 |
Wheat Germ Agglutinin |
| Cyr61 |
Luciferase |
YAP |
| Cystatin |
MAP2 |
|
Multiplex panels
| . |
| CD3/CD8/CD226/CD155/TIGIT |
| Checkpoint Inhibitors (CKI) CD3/CD8/PD-1/PD-L1/IDO |
Checkpoint Inhibitors (CKI) Tim3, SIRPa, E-Cadherin,
TIGIT, CD155, CTLA-4, Lag3, CD47, 4-1BB, CD226 |
| Liver Tumor Temperature CD3/CD8/Arginase 1 |
| Lung Tumor Temperature CD3/CD8/TTF-1 |
| M1/M2 CD68/CD163/c-MAF/pSTAT1 |
| MDSC CD11b/CD15/CD14/HLA-DR/LOX1 |
| SIRPa/CD3/CD11b/CD47 |
| Th Polarization (T-Bet/CD4/CD3/GATA3) |
| Treg Human CD3/CD8/CD4/CD25/FoxP3 |
| Treg Mice CD3/CD8/CD4/CD25/FoxP3/Vimentin |
Immunohistochemistry (IHC) at cerba research
Multiplex IHC offers the ability to measure up to 8 biomarkers simultaneously, allowing an improved understanding of spatial cellular context.
Tools are available to facilitate comprehensive immune profiling, investigation of tumor microenvironments and understanding the spatial context and co-expression of target biomarkers.
Automated slide digitization is possible for both chromogenic and fluorescent purposes, alongside enhanced software image analysis.
Multispectral scanning and imaging solutions are ideal in acquiring detailed morphological and protein expression information from cryosections, FFPE tissue or TMAs.
Technology and instrumentation for IHC
Cerba Research leverages some of the most cutting-edge technology and equipment for its biomarker research. These include:
- Leica Bond RX
- Leica Bond III
- Ventana Discovery XT Ultra
- Ventana Benchmark XT Ultra
- Dako Autostainer Link 48
- PerkinElmer/Akoya Vectra®
Polaris™ Hamamatsu Nanozoomer
Histoselect: antibody selection
Over 150 validated markers are available for on-demand combination and validation via strict quality controls. These can be employed in the generation of new FFPE IHC-specific antibodies.
About Cerba Research
For over 35 years, Cerba Research has been setting the industry standard for exemplary clinical trial conduct. Today, across five continents, with a focus on precision medicine, we are changing the paradigm of the central lab’s role in complex clinical research.
From protocol inception through development and to market, our passionate experts deliver the highest quality specialized and personalized laboratory and diagnostic solutions. Partner with us for the most efficient strategy to actualize your biotech and pharmaceutical products sooner and improve the lives of patients worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.